
Staff scientist @UCSF. Formerly @UCBerkeley, @HHMINEWS.
San Francisco
Joined May 2011
- Tweets102
- Following181
- Followers63
- Likes101
Daniel Sirkis retweeted
Five years ago we sketched out the designs for our first epigenome editors. Proud to see those sketches move into the clinic.
You can read more about the technology underpinning our epi-editors in this preprint we recently presented at ASGCT: biorxiv.org/content/10.64898…
Announcing our first clinical trial.
Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD).
Details🧵
Daniel Sirkis retweeted
Transforming traditional views laid by “CNS immune privilege,” our research uncovers the brain’s purposeful presentation of self – that is the brain engages with the immune system through “guardian” peptides to ensure immune tolerance. @jonykipnis
nature.com/articles/s41586-0…
Daniel Sirkis retweeted
Check out our new preprint showing our ability to use epigenetic age measured from blood to predict AD progression & cortical atrophy! @dwsir @UCSFimaging @UCSFmac @nanosanta @AgustinMIbanez @Cornell researchsquare.com/article/r…
Daniel Sirkis retweeted
New paper out📢! Toxic effects of IFN-I in humans has been suggested in patients with rare monogenic autoinflammatory diseases (SAVI, CANDLE, AGS) where IFN-I are elevated. In the absence of specific inhibitors, their causal role has been difficult to prove. We now report benefit of specific anti-IFNAR1 (#Anifrolumab) in 5 patients verifying the causal role of IFN-I in these diseases: rdcu.be/dXWPw
Daniel Sirkis retweeted
For the first time in 114 years, biologists from the Oregon Department of Fish and Wildlife have observed a fall-run Chinook salmon returning to spawn in the Klamath Basin in Oregon, after dam removal.
Daniel Sirkis retweeted
Circulatory proteins shape microglia state and boost phagocytosis!!!!! biorxiv.org/content/10.1101/…
Daniel Sirkis retweeted
Continuing with #crossreactivity and #TCR Another paper that I #love We simply #cant #afford to have "#holes" in the #repertoire. Virus-Specific CD4 Memory-Phenotype T Cells Are Abundant in Unexposed... sciencedirect.com/science/ar…
Daniel Sirkis retweeted
Learn about the intriguing connections between neurodegenerative & neuropsychiatric diseases 🪢 via alterations in interferon signaling! 🧠
@dwsir @AlexisOddi @C_WSolsberg @UCSFmac @DataTecnica @FTDcwow @GBHI_Fellows #WomenInSTEM
frontiersin.org/journals/psy…
Daniel Sirkis retweeted
HHMI Investigator Zhijian "James" Chen of @UTSWMedCenter has been named the 2024 Albert Lasker Basic Medical Research Award winner for his discovery of the DNA-sensing cGAS enzyme, which triggers immune & inflammatory responses. 👏
👉 hhmi.news/47wJnn2
Daniel Sirkis retweeted
A neurologist in Colombia, he worked with the world’s largest extended family with Alzheimer’s and helped fuel research to prevent or delay dementia symptoms. nyti.ms/3MGKozi
Daniel Sirkis retweeted
Incredibly excited to share our latest work exploring the antigen specificity of clonally-expanded CSF-enriched CD8+ T cells in MS #multiplesclerosis #Tcells #EBV 🧵1/
biorxiv.org/content/10.1101/…
Daniel Sirkis retweeted
Immortal quote from the amazing geneticist Gerry Fink…
“Just because it’s in Nature…
… doesn’t necessarily mean it’s wrong!”
Daniel Sirkis retweeted
We report many proteins not predicted by the genetic code.
They are stable & abundant O( 10³ ) copies / cell.
Generative mechanisms include codon-anticodon mismatches & RNA modifications.
Their abundance depends on codon frequency & protein stability.
biorxiv.org/content/10.1101/…
Daniel Sirkis retweeted
🚀 Excited for @YokoyamaLabUCSF to serve as Editor-in-Chief for @Nature_NPJ! #DementiaResearch #OpenAccess #cwowleads
Daniel Sirkis retweeted
I am thrilled to announce the launch of npj Dementia, for which I will be serving as the Editor-in-Chief. npj Dementia will be fully-open access and publish research that advances the field towards effective disease interventions. (1/3)
Announcing npj Dementia, an exciting new Nature Portfolio journal, led by EIC Dr Jen Yokoyama. nature.com/npjdementia/
Daniel Sirkis retweeted
Announcing npj Dementia, an exciting new Nature Portfolio journal, led by EIC Dr Jen Yokoyama. nature.com/npjdementia/
Daniel Sirkis retweeted
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease nejm.org/doi/full/10.1056/NE…
Daniel Sirkis retweeted
Check out the data that goes along with our new manuscript & conduct an exciting secondary analysis of your own! @RCFNeuro @alzdemjournals
New data from the @YokoyamaLabUCSF and @UCSFmac is now available on AD Workbench. Researchers can use this dataset to identify novel disease associations, cell-specific impacts, and therapeutic targets for Alzheimer’s.
Access data via AD Workbench: bit.ly/45C3zmA
Daniel Sirkis retweeted
New data from the @YokoyamaLabUCSF and @UCSFmac is now available on AD Workbench. Researchers can use this dataset to identify novel disease associations, cell-specific impacts, and therapeutic targets for Alzheimer’s.
Access data via AD Workbench: bit.ly/45C3zmA



























